Bicycle Therapeutics PLC (NASDAQ: BCYC) recently presented updated clinical results for its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The data revealed promising advancements across its various therapeutic candidates.
Zelenectide Pevedotin, a bicycle toxin conjugate (BTC®) targeting Nectin-4, demonstrated a 45% overall response rate (ORR) and an 11.1-month median duration of response in metastatic urothelial cancer (MUC) patients who had not previously been treated with enfortumab vedotin.
BT5528, a BTC molecule targeting EPHA2, displayed an emerging differentiated safety profile and antitumor activity, including a 45% ORR in MUC patients at a 6.5 mg/m2 dose every two weeks.
The company reported relatively low frequency and severity of treatment-related peripheral neuropathy following monotherapy with Zelenectide Pevedotin and BT5528, with patients often able to continue therapy without modification.
Furthermore, BT7480, a Nectin-4 targeted CD137 agonist, demonstrated a favorable safety profile and preliminary antitumor activity in advanced Nectin-4-associated solid tumors.
The company's CEO, Kevin Lee, expressed satisfaction with the presented data, highlighting the potential of Bicycle's technology platform to create differentiated medicines that not only extend patients' lives but also improve their quality of life.
The results from the ongoing phase 2/3 Duravelo-2 trial for Zelenectide Pevedotin in patients with MUC are currently enrolling, with additional data updates planned for later this year. Additionally, the company aims to share initial imaging data from its growing radiopharmaceutical pipeline and additional data for Zelenectide Pevedotin in bladder, breast, and lung cancer in the coming months.
Bicycle Therapeutics is committed to developing a novel class of medicines called Bicycle® molecules, which are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry, making them attractive candidates for drug development.
The company is headquartered in Cambridge, UK, with key functions and members of its leadership team located in Cambridge, Massachusetts. As a result of these announcements, the company's shares have moved 3.4% on the market, and are now trading at a price of $25.2. For more information, read the company's full 8-K submission here.
